Compare SRRK & M Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | M |
|---|---|---|
| Founded | 2012 | 1830 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.5B |
| IPO Year | 2018 | 2003 |
| Metric | SRRK | M |
|---|---|---|
| Price | $53.87 | $22.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $56.17 | $20.09 |
| AVG Volume (30 Days) | 1.0M | ★ 6.1M |
| Earning Date | 05-07-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 3.97% |
| EPS Growth | N/A | ★ 12.08 |
| EPS | N/A | ★ 0.85 |
| Revenue | N/A | ★ $22,621,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $534.24 | N/A |
| P/E Ratio | ★ N/A | $96.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.07 | $16.41 |
| 52 Week High | $61.76 | $26.59 |
| Indicator | SRRK | M |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 43.89 |
| Support Level | $44.26 | $19.80 |
| Resistance Level | $58.49 | $22.92 |
| Average True Range (ATR) | 2.35 | 0.81 |
| MACD | -0.38 | -0.05 |
| Stochastic Oscillator | 23.61 | 58.49 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.